alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2015016EN.01001601.xml

| 19.1.2015 | EN | Official Journal of the European Union | C 16/16 |
| --- | --- | --- | --- |

19.1.2015

EN

Official Journal of the European Union

C 16/16

---

Request submitted by Philippe Adam Krikorian (France) on 13 May 2014

(Case C-243/14)

(2015/C 016/24)

Language of the case: French

Parties to the main proceedings

Grégoire Krikorian and Others

Request concerning, first, the validity of Article 1(4) of Council Framework Decision 2008/913/JHA of 28 November 2008 on combating certain forms and expressions of racism and xenophobia by means of criminal law (OJ 2008 L 328, p. 55), and, secondly, the interpretation of that Council Framework Decision as well as Articles 6(1) and 13 of the European Convention for the Protection of Human Rights and Fundamental Freedoms, signed in Rome on 4 November 1950, Article 47 of the Charter of Fundamental Rights of the European Union, and, finally, Articles 4(3) TEU and the second subparagraph of Article 19(1) TEU.

---
§ 820.160 Distribution. ( a ) Each manufacturer shall establish and maintain procedures for control and distribution of finished devices to ensure that only those devices approved for release are distributed and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. Where a device's fitness for use or quality deteriorates over time, the procedures shall ensure that expired devices or devices deteriorated beyond acceptable fitness for use are not distributed.
( b ) Each manufacturer shall maintain distribution records which include or refer to the location of: ( 1 ) The name and address of the initial consignee;
( 2 ) The identification and quantity of devices shipped;
( 3 ) The date shipped; and
( 4 ) Any control number(s) used.
<TABLE> <S> <C>


<ARTICLE>                     5

<CIK>                                          947011
<NAME>                                         Royce Biomedical, Inc.
<MULTIPLIER>                                   1
<CURRENCY>                                     U.S.

<S>                             <C>
<PERIOD-TYPE>                                  12-MOS
<FISCAL-YEAR-END>                              JUN-30-2000
<PERIOD-START>                                 JUL-01-1999
<PERIOD-END>                                   JUN-30-2000
<EXCHANGE-RATE>                                1
<CASH>                                         137,655
<SECURITIES>                                   0
<RECEIVABLES>                                  824
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               138,992
<PP&E>                                         0
<DEPRECIATION>                                 0
<TOTAL-ASSETS>                                 138,992
<CURRENT-LIABILITIES>                          127,476
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       14,296
<OTHER-SE>                                     (40,289)
<TOTAL-LIABILITY-AND-EQUITY>                   138,992
<SALES>                                        46,800
<TOTAL-REVENUES>                               30,126
<CGS>                                          18,000
<TOTAL-COSTS>                                  189,711
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             0
<INCOME-PRETAX>                                (159,585)
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            (159,585)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (159,585)
<EPS-BASIC>                                    (0.05)
<EPS-DILUTED>                                  (0.05)



</TABLE>
§ 82.51 Lakes (FD&C). ( a ) ( 1 ) *General.* Any lake made by extending on a substratum of alumina, a salt prepared from one of the certified water-soluble straight colors hereinbefore listed in this subpart by combining such color with the basic radical aluminum or calcium.
( 2 ) *Specifications.* Prepared from previously certified colors listed in this subpart. Soluble chlorides and sulfates (as sodium salts), not more than 2.0 percent. Inorganic matter, insoluble HCl, not more than 0.5 percent.
( b ) Each lake made as prescribed in paragraph (a) of this section shall be considered to be a straight color and to be listed therein under the name which is formed as follows: ( 1 ) The listed name of the color from which the lake is prepared;
( 2 ) The name of the basic radical combined in such color; and
( 3 ) The word “Lake”.
(For example, the name of a lake prepared by extending the aluminum salt prepared from FD&C Blue No. 1 upon the substratum would be FD&C Blue No. 1—Aluminum Lake.)
RICHARD CHRISTINSEN,

Appellant,

v.

STATE OF FLORIDA,

Appellee.

IN THE DISTRICT COURT OF APPEAL

FIRST DISTRICT, STATE OF FLORIDA

NOT FINAL UNTIL TIME EXPIRES TO 

FILE MOTION FOR REHEARING AND 

DISPOSITION THEREOF IF FILED

CASE NO. 1D16-0429

_____________________________/

Opinion filed July 22, 2016.

An appeal from an order of the Circuit Court for Duval County.

Mallory D. Cooper, Judge.

Nancy A. Daniels, Public Defender, and Steven L. Seliger, Assistant Public 

Defender, Tallahassee, for Appellant.

Pamela Jo Bondi, Attorney General, Tallahassee, for Appellee.

PER CURIAM.

AFFIRMED.

BILBREY, KELSEY, and M. K. THOMAS, JJ., CONCUR.
EXHIBIT
32.2





CERTIFICATION
OF CHIEF FINANCIAL OFFICER





Pursuant
to Section 906 of the Sarbanes Oxley Act of 2002 (18 U.S.C. 1350)
and


Rules
13a-14(b) of the Securities Exchange Act of 1934







I,
Dominick Ragone, Chief Financial Officer of Icahn Enterprises G.P. Inc., the
general partner of Icahn Enterprises L.P., certify that, to the best of my
knowledge, based upon a review of the Icahn Enterprises L.P. quarterly report on
Form 10-Q for the period ended September 30, 2010 of the
registrant:




(1) The
report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended; and




(2) The
information contained in the report fairly presents, in all material respects,
the financial condition and results of operations of the
registrant.




/s/  Dominick
      RagoneDominick
      RagoneChief
      Financial Officer of Icahn Enterprises G.P. Inc., the general
                partner
      of Icahn Enterprises L.P.





Date:
November 5, 2010
EX-32                                    SECTION 1350 CERTIFICATION

                         SECTION 1350 CERTIFICATION

In connection with the quarterly report of W-J International,
Ltd. ("Company") on Form 10-QSB for the quarter ended December 31,
2003 as filed with the Securities and Exchange Commission ("Report"),
the undersigned, in the capacity and on the date indicated below,
hereby certifies pursuant to Section 906 of the Sarbanes-Oxley Act of
2002 (18 U.S.C. Section 1350) that to his knowledge:

1.  The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and

2.  The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Company.


Dated: February 10, 2004               By: /s/  Edward H. Webb
                                       Edward H. Webb, President
§ 58.107 Test and control article handling. Procedures shall be established for a system for the handling of the test and control articles to ensure that: ( a ) There is proper storage.
( b ) Distribution is made in a manner designed to preclude the possibility of contamination, deterioration, or damage.
( c ) Proper identification is maintained throughout the distribution process.
( d ) The receipt and distribution of each batch is documented. Such documentation shall include the date and quantity of each batch distributed or returned.
<PAGE>

                                                                    EXHIBIT 13.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Deswell Industries, Inc. (the "Company")
on Form 20-F for the year ended March 31, 2004 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), the undersigned hereby
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, to the best of our knowledge, that:

         (1) The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

Date: July 16, 2004                              By: /s/ Richard Lau
                                                     ------------------------
                                                     Richard Lau
                                                     Chief Executive Officer

Date: July 16, 2004                              By: /s/ C. P. Li
                                                     -----------------------
                                                     C. P. Li
                                                     Chief Financial Officer
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1335 Glucagon test system. ( a ) *Identification.* A glucagon test system is a device intended to measure the pancreatic hormone glucagon in plasma and serum. Glucagon measurements are used in the diagnosis and treatment of patients with various disorders of carbohydrate metabolism, including diabetes mellitus, hypoglycemia, and hyperglycemia.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2306, Jan. 14, 2000]
<PAGE>
                    EXHIBIT 32.2 - CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Evergreen Solar, Inc. (the "Company") on
Form 10-K/A for the period ended December 31, 2004 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Richard G.
Chleboski, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

/s/ Richard G. Chleboski

--------------------------------------------
Richard G. Chleboski
Chief Financial Officer
April 29, 2005
§ 70.5 General restrictions on use of color additives. ( a ) *Color additives for use in the area of the eye.* No listing or certification of a color additive shall be considered to authorize the use of any such color additive in any article intended for use in the area of the eye unless such listing or certification of such color additive specifically provides for such use. Any color additive used in or on any article intended for use in the area of the eye, the listing or certification of which color additive does not provide for such use, shall be considered to be a color additive not listed under parts 73, 74, and 81 of this chapter, even though such color additive is certified and/or listed for other uses.
( b ) *Color additives for use in injections.* No listing or certification of a color additive shall be considered to authorize the use of any such color additive in any article intended for use in injections unless such listing or certification of such color additive specifically provides for such use. Any color additive used in or on any article intended for use in injections, the listing or certification of which color additive does not provide for such use, shall be considered to be a color additive not listed under parts 73, 74, and 81 of this chapter, even though such color additive is certified and/or listed for other uses.
( c ) *Color additives for use in surgical sutures.* No listing or certification of a color additive shall be considered to authorize the use of any such color additive in any article intended for use as a surgical suture unless such listing or certification of such color additive specifically provides for such use. Any color additive used in or on any article intended for use as a surgical suture, the listing or certification of which color additive does not provide for such use, shall be considered to be a color additive not listed under parts 73, 74, and 81 of this chapter, even though such color additive is certified and/or listed for other uses.
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JAN-01-2000
<PERIOD-END>                                   SEP-30-2000
<CASH>                                             382,105
<SECURITIES>                                             0
<RECEIVABLES>                                       60,432
<ALLOWANCES>                                             0
<INVENTORY>                                        139,236
<CURRENT-ASSETS>                                   602,400
<PP&E>                                             231,770
<DEPRECIATION>                                      79,550
<TOTAL-ASSETS>                                     765,438
<CURRENT-LIABILITIES>                              679,323
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                         17,222
<COMMON>                                            32,219
<OTHER-SE>                                          36,674
<TOTAL-LIABILITY-AND-EQUITY>                       765,438
<SALES>                                            202,230
<TOTAL-REVENUES>                                   202,230
<CGS>                                              144,286
<TOTAL-COSTS>                                    1,561,322
<OTHER-EXPENSES>                                   (60,377)
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                  45,847
<INCOME-PRETAX>                                 (1,488,848)
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                                      0
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                    (1,488,848)
<EPS-BASIC>                                          (0.05)
<EPS-DILUTED>                                        (0.05)



</TABLE>
<PAGE>



                                   Exhibit 11


                 STATEMENT RE: COMPUTATION OF PER SHARE EARNINGS
                  (amounts in thousands, except per share data)
                                   (unaudited)

<TABLE>
<CAPTION>


                                                  Three Months Ended June 30,       Six Months Ended June 30,
                                                  ---------------------------       -------------------------
                                                       1998            1997           1998              1997
                                                       ----            ----           ----             ----
<S>                                                  <C>             <C>             <C>             <C>    

Net income                                           $ 4,491         $ 3,730         $12,862         $ 7,149
Weighted average common shares outstanding             7,573           7,524           7,573           7,520
Basic earnings per share                             $  0.59         $  0.50         $  1.70         $  0.95
                                                     -------         -------         -------         -------
                                                     -------         -------         -------         -------

Net income                                           $ 4,491         $ 3,730         $12,862         $ 7,149
Adjustments net of tax:
     Interest expense on convertible debt                786             823           1,554           1,652
     Amortization of debt offering costs                  61              64             121             129
                                                     -------         -------         -------         -------
Diluted net income                                   $ 5,338         $ 4,617         $14,537         $ 8,930
                                                     -------         -------         -------         -------
                                                     -------         -------         -------         -------

Weighted average common shares outstanding             7,573           7,524           7,573           7,520
Common stock equivalents due to dilutive
     effect of stock options                             226             196             222             196
Shares converted from convertible debt                 2,628           2,628           2,628           2,628
                                                     -------         -------         -------         -------
Total outstanding shares for diluted earnings
     per share computation                            10,427          10,348          10,423          10,344
Diluted earnings per share                           $  0.51         $  0.45         $  1.39         $  0.86
                                                     -------         -------         -------         -------
                                                     -------         -------         -------         -------
</TABLE>
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM PIMCO
ADVISORS HOLDINGS L.P. FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               MAR-31-1999
<CASH>                                          15,076
<SECURITIES>                                         0
<RECEIVABLES>                                   32,775
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                47,851
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 505,736
<CURRENT-LIABILITIES>                           46,881
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       458,855<F1>
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   505,736
<SALES>                                              0<F2>
<TOTAL-REVENUES>                                14,357
<CGS>                                                0<F2>
<TOTAL-COSTS>                                        0<F2>
<OTHER-EXPENSES>                                 3,662
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 10,695
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                             10,695
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    10,695
<EPS-PRIMARY>                                     0.22
<EPS-DILUTED>                                     0.21
<FN>
<F1>Entity is a partnership. Amount shown represents Partners' Capital.
<F2>The partnership is in the service business and has no sales or cost of good
sold on tangible products.
</FN>
        

</TABLE>
Dear Mr

. Power :

This letter is to inform you that the following information is missing fro m your petition (Docket No. FAA−2015

− 5493 )

. This information is necessary for the Federal Aviation Administration (FAA) to process your petition.

 Describe the aircraft make (s) , model (s) , and type(s)(i.e. , fixed

- wing, rotorcraft, lighter

- than

- air) for the proposed UAS operation. The description (s) should include the maximum weight ( including payload)

. This information can be located in the aircraft manual(s).
Please submit the additional information (non

- proprietary) to y our docket at www.regulations.gov

. Once your information has been submitted, please also send a copy of the requested information (and any proprietary information ), as well as your comment tracking number from regulations.gov via e

- mail to 333exemptions@faa.gov

. If you want us to process your request any further, we must receive the information described above by 1/29/16 . I f we do not receive the information , we will close the dock et without notifying you further. If you have any questions, please feel free to contact me at (202) 267

– 4549

. Sincerely, /S/ Michael J. Cameron Program Analyst
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

 Respondent

 v.

JOSE BRIGGS,

 Petitioner

:

:

:

:

:

:

:

:

:

:

:

No. 381 EAL 2014

Petition for Allowance of Appeal from the

Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 26th day of November, 2014, the Petition for Allowance of

Appeal is DENIED.
[Federal Register Volume 75, Number 36 (Wednesday, February 24, 2010)]
[Notices]
[Page 8401]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3856]


-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[USITC SE-10-002]


Government in the Sunshine Act Meeting Notice

AGENCY HOLDING THE MEETING: United States International Trade 
Commission.

TIME AND DATE: February 26, 2010 at 9:30 a.m.

PLACE: Room 110, 500 E Street, SW., Washington, DC 20436, Telephone: 
(202) 205-2000.

STATUS: Open to the public.

MATTERS TO BE CONSIDERED:
    1. Agenda for future meetings: none.
    2. Minutes.
    3. Ratification List.
    4. Inv. No. AA1921-167 (Third Review) (Pressure Sensitive Plastic 
Tape from Italy)--briefing and vote. (The Commission is currently 
scheduled to transmit its determination and Commissioners' opinions to 
the Secretary of Commerce on or before March 11, 2010.)
    5. Outstanding action jackets: none.
    In accordance with Commission policy, subject matter listed above, 
not disposed of at the scheduled meeting, may be carried over to the 
agenda of the following meeting.

    By order of the Commission.

    Issued: February 19, 2010.
William R. Bishop,
Hearings and Meetings Coordinator.
[FR Doc. 2010-3856 Filed 2-22-10; 4:15 pm]
BILLING CODE 7020-02-P